
PMC:7279430 / 24288-25114
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T63 | 271-274 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T64 | 285-288 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T65 | 362-369 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T66 | 485-493 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
953 | 141-145 | Gene | denotes | Mpro | Gene:8673700 |
954 | 312-316 | Gene | denotes | RdRp | Gene:43740578 |
955 | 356-361 | Gene | denotes | spike | Gene:43740568 |
956 | 397-426 | Gene | denotes | angiotensin-converting enzyme | Gene:1636 |
957 | 428-433 | Gene | denotes | hACE2 | Gene:59272 |
958 | 104-114 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
959 | 130-140 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
960 | 148-158 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
961 | 178-188 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
962 | 204-214 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
963 | 242-252 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
964 | 260-270 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
965 | 301-311 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
966 | 345-355 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
967 | 371-381 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
968 | 391-396 | Species | denotes | human | Tax:9606 |
969 | 469-477 | Species | denotes | SARS-CoV | Tax:694009 |
970 | 502-506 | Species | denotes | E)-α | Tax:114629 |
971 | 518-533 | Chemical | denotes | (E)-β-farnesene | |
972 | 539-553 | Chemical | denotes | (E,E)-farnesol | |
973 | 669-682 | Chemical | denotes | essential oil | MESH:D009822 |
974 | 719-733 | Chemical | denotes | essential oils | MESH:D009822 |
975 | 808-816 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T128 | 104-112 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T129 | 130-138 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T130 | 148-156 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T131 | 178-186 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T132 | 204-212 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T133 | 242-250 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T134 | 260-268 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T135 | 301-309 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T136 | 345-353 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T137 | 371-379 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T138 | 469-477 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T139 | 808-816 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T166 | 15-16 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T167 | 382-384 | http://purl.obolibrary.org/obo/CLO_0008882 | denotes | rS |
T168 | 391-396 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T169 | 645-650 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T381 | 70-94 | Chemical | denotes | essential oil components | http://purl.obolibrary.org/obo/CHEBI_27311 |
T382 | 70-83 | Chemical | denotes | essential oil | http://purl.obolibrary.org/obo/CHEBI_83630 |
T383 | 215-218 | Chemical | denotes | ADP | http://purl.obolibrary.org/obo/CHEBI_16761|http://purl.obolibrary.org/obo/CHEBI_456216|http://purl.obolibrary.org/obo/CHEBI_73342 |
T386 | 219-225 | Chemical | denotes | ribose | http://purl.obolibrary.org/obo/CHEBI_33942|http://purl.obolibrary.org/obo/CHEBI_47013 |
T388 | 362-369 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T389 | 397-408 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
T390 | 453-460 | Chemical | denotes | ligands | http://purl.obolibrary.org/obo/CHEBI_52214 |
T391 | 485-493 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T392 | 507-516 | Chemical | denotes | farnesene | http://purl.obolibrary.org/obo/CHEBI_39237 |
T393 | 524-533 | Chemical | denotes | farnesene | http://purl.obolibrary.org/obo/CHEBI_39237 |
T394 | 539-553 | Chemical | denotes | (E,E)-farnesol | http://purl.obolibrary.org/obo/CHEBI_16619 |
T395 | 545-553 | Chemical | denotes | farnesol | http://purl.obolibrary.org/obo/CHEBI_28600 |
T396 | 669-693 | Chemical | denotes | essential oil components | http://purl.obolibrary.org/obo/CHEBI_27311 |
T397 | 669-682 | Chemical | denotes | essential oil | http://purl.obolibrary.org/obo/CHEBI_83630 |
T398 | 719-733 | Chemical | denotes | essential oils | http://purl.obolibrary.org/obo/CHEBI_83630 |
T399 | 755-771 | Chemical | denotes | antiviral agents | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T17 | 229-240 | http://purl.obolibrary.org/obo/GO_0016791 | denotes | phosphatase |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T175 | 0-2 | Sentence | denotes | 4. |
T176 | 3-14 | Sentence | denotes | Conclusions |
T177 | 15-435 | Sentence | denotes | A molecular docking analysis was carried out using 171 essential oil components with the SARS-CoV-2 main protease (SARS-CoV-2 Mpro), SARS-CoV-2 endoribonucleoase (SARS-CoV-2 Nsp15/NendoU), SARS-CoV-2 ADP-ribose-1″-phosphatase (SARS-CoV-2 ADRP), SARS-CoV-2 RNA-dependent RNA polymerase (SARS-CoV-2 RdRp), the binding domain of the SARS-CoV-2 spike protein (SARS-CoV-2 rS), and human angiotensin-converting enzyme (hACE2). |
T178 | 436-554 | Sentence | denotes | The best docking ligands for the SARS-CoV target proteins were (E,E)-α-farnesene, (E)-β-farnesene, and (E,E)-farnesol. |
T179 | 555-659 | Sentence | denotes | The docking energies were relatively weak, however, and are unlikely to interact with the virus targets. |
T180 | 660-826 | Sentence | denotes | However, essential oil components may act synergistically, essential oils may potentiate other antiviral agents, or they may provide some relief of COVID-19 symptoms. |